Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Deutsche Bank AG (DB) vs Twist Bioscience Corp (TWST) Price & Performance

Deutsche Bank AGTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Deutsche Bank AG vs Twist Bioscience Corp — how do they compare? Deutsche Bank AG trades at $33.7 (market cap $63.13B), while Twist Bioscience Corp trades at $157.83 (market cap $10.32B). The key difference: Deutsche Bank AG is far larger — about 6.1× Twist Bioscience Corp's market cap, and Deutsche Bank AG pays a 3.47% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Twist Bioscience Corp for 27 Days on average.

DBTWST
Market Cap
$63.13B$10.32B
Volume
3,260,4885,894,998
Sector
FinancialsHealth
52-Week High
$41.56$205.00
52-Week Low
$28.37$25.45
Typical Hold Time
80 Days27 Days
Enterprise Value
$75.71B$10.24B
Dividend Yield
3.47%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Deutsche Bank AG

Deutsche Bank (DB) trades at $33.63, down 4.27% amid a bearish technical signal. The stock shows attractive valuation with a P/E of 9.1 and P/B of 0.71, while recent earnings beat expectations in two of the last three quarters. Net income surged to $6.93B in 2025, though Q3 2026 investment bank revenue is expected flat to slightly down. Cash flow improved significantly with net cash flow of $7.61B in 2025.

The outlook is mixed: strong fundamentals and low valuation support upside, but bearish technicals and cautious analyst consensus (57.58% hold) indicate near-term headwinds. Key risks include revenue volatility in investment banking and macroeconomic sensitivity. The stock offers value potential if execution on 2028 targets holds.

Twist Bioscience Corp

TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.

The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DB
100% Buy0% Sell
Avg holding period · 80 Days
TWST
37% Buy63% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Deutsche Bank AG

In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.

Read more on DB →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →